224 related articles for article (PubMed ID: 27042030)
21. [A year of chronic pain with Targin--experience from daily practice. Interview with Dr. Patricia Fehlmann].
Fehlmann P
Rev Med Suisse; 2011 Jun; 7(301):preceding 1414. PubMed ID: 21815498
[No Abstract] [Full Text] [Related]
22. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial.
Matucci-Cerinic M; Denton CP; Furst DE; Mayes MD; Hsu VM; Carpentier P; Wigley FM; Black CM; Fessler BJ; Merkel PA; Pope JE; Sweiss NJ; Doyle MK; Hellmich B; Medsger TA; Morganti A; Kramer F; Korn JH; Seibold JR
Ann Rheum Dis; 2011 Jan; 70(1):32-8. PubMed ID: 20805294
[TBL] [Abstract][Full Text] [Related]
23. Targinact--opioid pain relief without constipation?
Drug Ther Bull; 2010 Dec; 48(12):138-41. PubMed ID: 21123290
[TBL] [Abstract][Full Text] [Related]
24. A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation.
Meissner W; Leyendecker P; Mueller-Lissner S; Nadstawek J; Hopp M; Ruckes C; Wirz S; Fleischer W; Reimer K
Eur J Pain; 2009 Jan; 13(1):56-64. PubMed ID: 18762438
[TBL] [Abstract][Full Text] [Related]
25. Oxycodone in the long-term treatment of chronic pain related to scleroderma skin ulcers.
Giuggioli D; Manfredi A; Colaci M; Ferri C
Pain Med; 2010 Oct; 11(10):1500-3. PubMed ID: 20456083
[TBL] [Abstract][Full Text] [Related]
26. Ischemic digital ulcers affect hand disability and pain in systemic sclerosis.
Mouthon L; Carpentier PH; Lok C; Clerson P; Gressin V; Hachulla E; Bérezné A; Diot E; Khau Van Kien A; Jego P; Agard C; Duval-Modeste AB; Sparsa A; Puzenat E; Richard MA;
J Rheumatol; 2014 Jul; 41(7):1317-23. PubMed ID: 24931950
[TBL] [Abstract][Full Text] [Related]
27. Combined oral prolonged-release oxycodone and naloxone in opioid-induced bowel dysfunction: review of efficacy and safety data in the treatment of patients experiencing chronic pain.
Clemens KE; Mikus G
Expert Opin Pharmacother; 2010 Feb; 11(2):297-310. PubMed ID: 20030568
[TBL] [Abstract][Full Text] [Related]
28. Increases in controlled-release oxycodone utilisation following the subsidy of oxycodone with naloxone formulations: An Australian population-based study.
Schaffer AL; Karanges EA; Buckley NA; Wilson A; Degenhardt L; Larance B; Pearson SA
Pharmacoepidemiol Drug Saf; 2019 Jan; 28(1):97-105. PubMed ID: 30421838
[TBL] [Abstract][Full Text] [Related]
29. Elucidating the burden of recurrent and chronic digital ulcers in systemic sclerosis: long-term results from the DUO Registry.
Matucci-Cerinic M; Krieg T; Guillevin L; Schwierin B; Rosenberg D; Cornelisse P; Denton CP
Ann Rheum Dis; 2016 Oct; 75(10):1770-6. PubMed ID: 26612339
[TBL] [Abstract][Full Text] [Related]
30. [New study demonstrates dual effect of an oxycodone/naloxone combination. Strong pain palliation and preserving intestinal function].
MMW Fortschr Med; 2007 Nov; 149(48):50. PubMed ID: 18161439
[No Abstract] [Full Text] [Related]
31. Oxycodone with an opioid receptor antagonist: A review.
Davis MP; Goforth HW
J Opioid Manag; 2016; 12(1):67-85. PubMed ID: 26908305
[TBL] [Abstract][Full Text] [Related]
32. What narrative devices do people with systemic sclerosis use to describe the experience of pain from digital ulcers: a multicentre focus group study at UK scleroderma centres.
Jones J; Hughes M; Pauling J; Gooberman-Hill R; Moore AJ
BMJ Open; 2020 Jun; 10(6):e037568. PubMed ID: 32532783
[TBL] [Abstract][Full Text] [Related]
33. Autologous fat grafting for scleroderma-induced digital ulcers. An effective technique in patients with systemic sclerosis.
Bene MD; Pozzi MR; Rovati L; Mazzola I; Erba G; Bonomi S
Handchir Mikrochir Plast Chir; 2014 Aug; 46(4):242-7. PubMed ID: 25162242
[TBL] [Abstract][Full Text] [Related]
34. Innovative pain therapy with a fixed combination of prolonged-release oxycodone/naloxone: a large observational study under conditions of daily practice.
Schutter U; Grunert S; Meyer C; Schmidt T; Nolte T
Curr Med Res Opin; 2010 Jun; 26(6):1377-87. PubMed ID: 20380506
[TBL] [Abstract][Full Text] [Related]
35. Digital ulcers in scleroderma patients: A retrospective observational study.
De Cata A; Inglese M; Molinaro F; De Cosmo S; Rubino R; Bernal M; Mazzoccoli G
Int J Immunopathol Pharmacol; 2016 Jun; 29(2):180-7. PubMed ID: 26684622
[TBL] [Abstract][Full Text] [Related]
36. Potential drug interaction with opioid agonist in the setting of chronic low-dose opioid antagonist use.
Leonard JB; Nair V; Diaz CJ; Penoyar JB; Goode PA
Am J Emerg Med; 2017 Aug; 35(8):1209.e3-1209.e4. PubMed ID: 28410920
[TBL] [Abstract][Full Text] [Related]
37. Digital ulcers: overt vascular disease in systemic sclerosis.
Steen V; Denton CP; Pope JE; Matucci-Cerinic M
Rheumatology (Oxford); 2009 Jun; 48 Suppl 3():iii19-24. PubMed ID: 19487218
[TBL] [Abstract][Full Text] [Related]
38. [General practice study reveals simplification of therapy for physician and patients. Patient satisfaction and better quality of life].
MMW Fortschr Med; 2007 Nov; 149(48):51. PubMed ID: 18163263
[No Abstract] [Full Text] [Related]
39. Oxycodone + naloxone: choose morphine and optimal laxative therapy instead.
Prescrire Int; 2013 Jan; 22(134):10-1. PubMed ID: 23367675
[TBL] [Abstract][Full Text] [Related]
40. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers.
Abou-Raya A; Abou-Raya S; Helmii M
J Rheumatol; 2008 Sep; 35(9):1801-8. PubMed ID: 18709692
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
